Engineered immune cells take aim at lupus and other autoimmune diseases
NCT ID NCT07174843
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This early-stage study is testing a new treatment called BZE2204 for people with three types of autoimmune diseases that have not responded to standard therapies: lupus, idiopathic inflammatory myopathies, and immune thrombocytopenia. The treatment uses a patient's own immune cells, which are modified in a lab to target and attack the faulty immune cells causing the disease. The main goals are to check the treatment's safety and to see if it can reduce disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Mengchao Cancer Hospital
RECRUITINGShanghai, Shanghai Municipality, 200240, China
Contact
Conditions
Explore the condition pages connected to this study.